These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 27751514)

  • 1. Non-alcoholic fatty liver disease and diabetes.
    Reyes-García R; Rozas-Moreno P; Llamoza-Torres CJ; Mezquita-Raya P
    Med Clin (Barc); 2017 Jan; 148(1):33-38. PubMed ID: 27751514
    [No Abstract]   [Full Text] [Related]  

  • 2. Managing non-alcoholic fatty liver disease in diabetes: Challenges and opportunities.
    Lee CH; Lam KS
    J Diabetes Investig; 2017 Mar; 8(2):131-133. PubMed ID: 27181498
    [No Abstract]   [Full Text] [Related]  

  • 3. Non-alcoholic fatty liver disease in patients with type 2 diabetes: diagnostic and therapeutic considerations.
    Paraschou EM; Shalit A; Paschou SA
    Hormones (Athens); 2024 Sep; 23(3):415-417. PubMed ID: 38093156
    [No Abstract]   [Full Text] [Related]  

  • 4. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) clinical practice recommendations for the management of non-alcoholic fatty liver disease: evaluation of their application in people with Type 2 diabetes.
    Sberna AL; Bouillet B; Rouland A; Brindisi MC; Nguyen A; Mouillot T; Duvillard L; Denimal D; Loffroy R; Vergès B; Hillon P; Petit JM
    Diabet Med; 2018 Mar; 35(3):368-375. PubMed ID: 29247558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In search of the optimal management strategy for non-alcoholic fatty liver disease in type 2 diabetes patients.
    Lee CH; Lui DT; Lam KS
    J Diabetes Investig; 2021 Apr; 12(4):482-484. PubMed ID: 32814360
    [No Abstract]   [Full Text] [Related]  

  • 6. Nonalcoholic fatty liver disease and type 2 diabetes: common pathophysiologic mechanisms.
    Saponaro C; Gaggini M; Gastaldelli A
    Curr Diab Rep; 2015 Jun; 15(6):607. PubMed ID: 25894944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The prospects for the application of the natural and preformed therapeutic factors in the treatment of non-alcoholic fatty liver disease].
    Zabolotnaya IB
    Vopr Kurortol Fizioter Lech Fiz Kult; 2016; 93(4):42-48. PubMed ID: 27500678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Advancement of researches on association of non-alcoholic fatty liver disease with type 2 diabetes mellitus].
    Gao X; Wang S
    Zhonghua Gan Zang Bing Za Zhi; 2014 Mar; 22(3):161-4. PubMed ID: 24919218
    [No Abstract]   [Full Text] [Related]  

  • 9. Prevalence and severity of non-alcoholic fatty liver disease are underestimated in clinical practice: impact of a dedicated screening approach at a large university teaching hospital.
    Marjot T; Sbardella E; Moolla A; Hazlehurst JM; Tan GD; Ainsworth M; Cobbold JFL; Tomlinson JW
    Diabet Med; 2018 Jan; 35(1):89-98. PubMed ID: 29094442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Practical approach to non-alcoholic fatty liver disease in patients with diabetes.
    Tai FW; Syn WK; Alazawi W
    Diabet Med; 2015 Sep; 32(9):1121-33. PubMed ID: 25683343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Non-alcoholic fatty liver disease and hepatocellular carcinoma - 2016].
    Pár A; Pár G
    Orv Hetil; 2016 Jun; 157(25):987-94. PubMed ID: 27287838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [State of intestinal microbiota in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease].
    Lytvynenko KO; Bodnar PM; Lysiana TO; Ponomar'ova IH; Koval'chuk OA
    Lik Sprava; 2014; (5-6):82-7. PubMed ID: 25906652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Non alcoholic steatohepatitis (NASH)].
    Coronel M E; Coronel C M
    Rev Gastroenterol Peru; 2016; 36(1):58-65. PubMed ID: 27131942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Not Available].
    Rauh C; Dufour JF
    Ther Umsch; 2017 Jul; 74(3):87-92. PubMed ID: 28777051
    [No Abstract]   [Full Text] [Related]  

  • 15. [The effectiveness of the spa and health resort-based treatment with the application of Essentuki-type drinking mineral waters for the management of non-alcoholic fatty liver disease in the patients presenting with type 2 diabetes mellitus].
    Efimenko NV; Kaĭsinova AS; Fedorova TE; Botvineva LA
    Vopr Kurortol Fizioter Lech Fiz Kult; 2015; 92(3):14-17. PubMed ID: 26285328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of high dose n-3 polyunsaturated fatty acid treatment on measures of microvascular function and vibration perception in non-alcoholic fatty liver disease: results from the randomised WELCOME trial.
    McCormick KG; Scorletti E; Bhatia L; Calder PC; Griffin MJ; Clough GF; Byrne CD
    Diabetologia; 2015 Aug; 58(8):1916-25. PubMed ID: 26021488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-alcoholic fatty liver disease.
    Pearce L
    Nurs Stand; 2016 Aug; 30(52):15. PubMed ID: 27641564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Liver diseases. Non-alcoholic fatty liver disease].
    Bernal Reyes R
    Rev Gastroenterol Mex; 2010 Aug; 75 Suppl 1():181-3. PubMed ID: 20959244
    [No Abstract]   [Full Text] [Related]  

  • 19. Intracellular lipid accumulation and shift during diabetes progression.
    Wolf P; Winhofer Y; Anderwald CH; Krššák M; Krebs M
    Wien Med Wochenschr; 2014 Aug; 164(15-16):320-9. PubMed ID: 25047370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-alcoholic fatty pancreas disease.
    Alempijevic T; Dragasevic S; Zec S; Popovic D; Milosavljevic T
    Postgrad Med J; 2017 Apr; 93(1098):226-230. PubMed ID: 28069746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.